Clinical TrialsBrisk enrollment into ONWARD suggests positive physician and patient perception of ESK-001 and demonstrates ALMS' strong clinical execution.
Market PotentialESK-001's performance in the psoriasis market shows promise, with potential to capture market share from existing biologic treatments.
Regulatory ApprovalThe potential accelerated regulatory path for ESK-001 in psoriasis, with a filing of 24-week results and subsequent submission of 52-week data, indicates confidence in the product's approval process.